Biopsy‐proven recurrence of endometriosis · women with endometriosis, following complete surgical excision of lesions
It is very uncertain whether raloxifene changes biopsy‐proven recurrence of endometriosis compared with placebo (very low certainty).
1 finding from 1 review
Incidence of depression ‐ short‐term: < 6 months · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes incidence of depression ‐ short‐term: < 6 months compared with placebo (very low certainty).
1 finding from 1 review
Incidence of depression ‐ medium term: 6‐12 months · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes incidence of depression ‐ medium‐term: 6‐12 months compared with placebo (very low certainty).
1 finding from 1 review
Incidence of depression ‐ long‐term: >12 months · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
Tolerability ‐ total number of adverse events · adults with long‐term physical conditions (18 years or older)
1 finding from 1 review
acceptability ‐ drop‐outs due to adverse events: post‐intervention · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes acceptability ‐ drop‐outs due to adverse events: post‐intervention compared with placebo (very low certainty).
1 finding from 1 review
Acceptability · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes acceptability ‐ drop‐outs due to any cause: post‐intervention compared with placebo (very low certainty).
2 findings from 1 review
Incidence of depression ‐ post‐intervention: 0 months · adults with long‐term physical conditions (18 years or older)
It is very uncertain whether pharmacological interventions changes incidence of depression ‐ post‐intervention: 0 months compared with placebo (very low certainty).
1 finding from 1 review
Partcipant assessment of success · glabellar lines
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher partcipant assessment of success compared with placebo (moderate certainty).
1 finding from 1 review
Duration of treatment effect · glabellar lines
1 finding from 1 review
Participant assessment of success by analysing scores and scales ‐ 4 weeks · glabellar lines
Summary of Findings Table ‐ IncobotulinumtoxinA 20U probably leads to higher participant assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
1 finding from 1 review
Major adverse events · glabellar lines
1 finding from 1 review
Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction) · glabellar lines
Summary of Findings Table ‐ IncobotulinumtoxinA 20U probably leads to higher physician assessment of success by analysing scores and scales compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events · glabellar lines
Summary of Findings Table ‐ IncobotulinumtoxinA 20U showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
Duration of treatment effect ‐ not measured · glabellar lines
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major adverse events · glabellar lines
Summary of Findings Table ‐ OnabotulinumtoxinA 20U probably leads to higher major adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Participant assessment of success by analysing scores and scales ‐ 4 weeks · glabellar lines
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher participant assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
1 finding from 1 review
Major adverse events · glabellar lines
1 finding from 1 review
Physician assessment of success by analysing scores and scales ‐ 4 weeks (Validated tools, wrinkles and lines at maximum contraction) · glabellar lines
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher physician assessment of success by analysing scores and scales ‐ 4… compared with placebo (moderate certainty).
1 finding from 1 review
Total adverse events · glabellar lines
Summary of Findings Table ‐ DaxibotulinumtoxinA 40U probably leads to higher total adverse events compared with placebo (moderate certainty).
1 finding from 1 review